DOCSLIB.ORG

Warfarin-Induced Skin Necrosis in Patients with Low Protein C Levels

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Warfarin-Induced Skin Necrosis in Patients with Low Protein C Levels CASE REPORT Warfarin-Induced Skin Necrosis in Patients With Low Protein C Levels Marino Marčić1, Ljiljana Marčić2, and Marina Titlić1 1 Department of Neurology, School of Medicine, University of Split, Split, Croatia 2 Department of Radiology, School of Medicine, University of Split, Split, Croatia Received: 31 Oct. 2014; Accepted: 28 May 2015 Abstract- Warfarin-induced skin necrosis (WISN) is a rare complication of anticoagulant therapy associated with a high incidence of morbidity and mortality requiring immediate drug cessation. At particular risk are those with various thrombophilic abnormalities, especially when warfarinisation is undertaken rapidly with large loading doses of warfarin. Cutaneous findings include petechiae that progress to ecchymosis and hemorrhagic bullae. With the increasing number of patients anticoagulated as out-patients for thromboprophylaxis, we are concerned that the incidence of skin necrosis may increase. We present a case of WISN with low protein C level. He was a 50-year-old male who came to our department because of acute infarction in irrigation area of the superior cerebellar artery. He had intermittent atrial fibrillation and was started on anticoagulant therapy. After few day of therapy, he developed skin necrosis, and his level of protein C was low. Warfarin-induced skin necrosis is a rare but serious complication that can be prevented by routine screening for protein C, protein S or antithrombin deficiencies or for the presence of antiphospholipid antibodies before beginning warfarin therapy. © 2016 Tehran University of Medical Sciences. All rights reserved. Acta Med Iran, 2016;54(8):551-554. Keywords: Anticoagulant; Coumarins; Warfarin; Thrombophilia; Protein C; Thrombosis Introduction necrotic (6). Dermal biopsy demonstrates ischemic necrosis of the cutaneous tissue with cutaneous vessel Stroke is one of the most significant risks associated thrombosis and surrounding interstitial hemorrhage with atrial fibrillation. Non-valvular atrial fibrillation (7,8). Protein C is a 62-kD, vitamin K-dependent (AF) is the most common cause of cardioembolic stroke glycoprotein synthesized in the liver. It circulates in the and a powerful risk factor for strokes with overall risk blood as an inactive zymogen at a concentration of 4 ranges from 2.5% to 4% per year (1). Oral μg/mL (9). Its activation into the serine-protease-like anticoagulants (OAC) reduce this risk, but also increase enzyme, activated protein C (aPC), is catalyzed by the risk of hemorrhagic stroke and major bleeding. thrombin when it is bound to the endothelial Among all other side-effects of warfarin therapy, skin proteoglycan thrombomodulin (10,11). Activated necrosis is a rare but serious (2). Warfarin-induced skin protein C (aPC) exerts its anticoagulant activity necrosis (WISN) occurs in only 0.01%-0.1% of patients primarily through inactivation of coagulation factors Va taking the drug (3). WISN develops mainly in middle- and VIIIa, which are required for factor X activation and aged women who are usually perimenopausal, obese and thrombin generation. The catalytic activity of activated have been treated for deep vein thrombosis or protein C (aPC) is greatly enhanced by the vitamin K- pulmonary embolism (4). The site of the lesion is dependent cofactor protein S (12). A deficiency of random and unpredictable, but the breast is the most activated protein C (aPC) disturbs the delicate balance common site in women, followed by the buttocks and between procoagulant and anticoagulant proteins and thighs. In men with WISN involvement of penile skin engenders a prothrombotic environment. The role of may is common (5). The skin lesions of WISN begin as activated protein C (aPC) and other anticoagulant erythematous macules and, if appropriate therapy is not proteins in this balance appear to be especially important initiated promptly, evolve to become purpuric and in the slow-flowing venous circulation, in which there is Corresponding Author: M. Marcic Department of Neurology, School of Medicine, University of Split, Split, Croatia Tel: +385 21 556550, Fax: +385 21 556550, E-mail address: [email protected] Warfarin-induced skin necrosis prolonged exposure of procoagulant proteins and intravenous unfractionated heparin, vitamin K, and fresh platelet phospholipids to the vessel wall. This may frozen plasma. Therapeutic heparinization, initially with explain, in part, why protein C deficiency appears to be unfractionated, then with low molecular weight heparin associated primarily with venous thrombosis. There is a was continued for two weeks, during which time her calf lot of causes of acquired protein C deficiency: acute began to heal. Because of the strong risk for another thrombosis, warfarin therapy, liver disease, vitamin K stroke, we introduced in therapy novel anticoagulant deficiency, sepsis, disseminated intravascular therapy (dabigatran, in daily doses of 300 mg). His calf coagulation (DIC) and hematopoietic stem cell healed with no permanent skin damage. After 6 months, transplantation (13,14). With the increasing number of he did not have any new neurological complications. patients’ anticoagulated as out-patients for thromboprophylaxis, incidence of skin necrosis may Discussion increase. Warfarin-induced skin necrosis is rare, but serious Case Report side effect of anticoagulant therapy. This side effect typically appears during the early 10 days of therapy. At A 50-year-old male, came to our department with particular risk are those with various thrombophilic ataxia, speech problems, nausea, and vomitus. He had abnormalities, especially when warfarinisation is irregular heart rhythm because of intermittent atrial undertaken rapidly with large loading doses of warfarin. fibrillation. During the examination, he was eupneic, The pathogenesis of WISN is still obscure. Thrombosis, afebrile, with irregular heart rhythm. In the neurologic hypersensitivity, hemorrhage, factor VII deficiency, examination, we noticed truncal ataxia, left-hand protein C and S deficiency, and direct toxic effects of dysmetria, and he was dysarthric. The platelet count was warfarin have been suggested as potential mechanisms, 220×103/µL. CT scan showed acute ischemic lesion in but other hypercoagulable conditions such as lupus irrigation territory of the superior cerebellar artery which anticoagulant, factor V Leiden or antithrombin III was confirmed by MR two days after. During deficiency have also been associated with skin necrosis. hospitalization newly diabetes mellitus was discovered, Some cases occur in association with a familial and peroral therapy was started. 24 hour ECG recording, deficiency of protein C or protein S, and hereditary showed intermittent atrial fibrillation. The cause of his protein C deficiency is considered a major risk factor. stroke was intermittent atrial fibrillation, and his Heterozygous protein C deficiency is inherited in an CHADS-VASC score was 5. autosomal dominant fashion. In type I deficiency, there is a quantitative deficiency in the plasma protein C concentration, and type II protein C deficiency is associated with decreased functional activity and normal immunologic levels of protein C We represented a patient with an embolic stroke which is a candidate for anticoagulant therapy. Because of high risk for the new embolic incident; initially, we gave him a warfarin in a total dosage of 5 mg, inspite of low levels of protein C. He developed skin necrosis the second day of therapy, so we discontinued warfarin. When warfarin therapy is started, there is a more rapid fall in the concentration of protein C than of the other vitamin-K-dependent Figure 1. Skin necrosis induced by warfarin procoagulant factors. The temporary hypercoagulable state which results is believed to lead to the development We introduced anticoagulant therapy with warfarin of WISN in susceptible individuals (16). The use of in a total dosage of 5 mg/D. He had low levels of protein large loading doses of warfarin may exacerbate this C (0.39, referent interval is 0.7-1.4). On the second day effect and particularly at risk are those with an inherited of anticoagulant therapy, his INR was 1.8, and he deficiency of protein C or other impairment of the developed an area of extremely tender erythema on her protein C pathway. Patients known to be at risk of left calf, surrounded by bruising. This was recognized as WISN (those with a previous episode, protein C or S early skin necrosis, and he was immediately treated with deficiency and, our data suggest, antiphospholipid 552 Acta Medica Iranica, Vol. 54, No. 8 (2016) M. Marcic, et al. antibodies) should also be warfarinised in this gradual protein C and S activity. Anadolu Kardiyol Derg way or treated with novel anticoagulant therapy, as what 2008;8:E22. have been done with our patients (17). A consequence of 5. ssex DW, Wynn SS, Jin DK. Late onset warfarin-induced the growth in the number of indications for warfarin skin necrosis: Case report and review of the literature. therapy is that many patients are now started on warfarin Am J Hematol 1998;57:233-7. and rapid warfarinisation in the out-patient setting 6. De Franzo AJ, Marasco P, Argenta LC. Warfarin-induced without concomitant heparinization may put some necrosis of the skin. Ann Plast Surg 1995;34:203-8. patients, such as those with undetected thrombophilic 7. Ad-El D, Meirovitz A, Weinberg A, Kogan L, Arieli D, abnormalities, at risk of WISN (18). The more gradual Neuman A, et al. Warfarin skin necrosis: Local and approach, using low-dose warfarin and aiming to systemic factors. Br J Plast Surg 2000;53:624-6. achieve a therapeutic INR in 10–12 days would lessen 8. Enzenauer RJ, Berenberg JL, Campbell J. Progressive this risk without compromising the treatment of patients warfarin anticoagulation in protein C deficiency: a who are being selectively anticoagulated. In patients therapeutic strategy. Am J Med 1990;88:697-8. with high risk for new embolic stroke and with known 9. Dahlbäck B. Protein S and C4b binding protein: risk of WISN (those with a previous episode, protein C components involved in the regulation of the protein C or S deficiency and, our data suggest, antiphospholipid anticoagulant system.
Load more

Recommended publications
  • An Atypical Case of Warfarin-Induced Skin Necrosis
    CASE REPORT An Atypical Case of Warfarin-Induced Skin Necrosis Lindsay R. Sklar, MD* *Wayne State University, Department of Dermatology, Dearborn, Michigan Anne Messman, MD, FACEP† †Sinai-Grace Hospital, Department of Emergency Medicine, Detroit, Michigan Section Editor: Rick A. McPheeters, DO Submission history: Submitted December 19, 2016; Revision received March 8, 2017; Accepted March 30, 2017 Electronically published October 11, 2017 Full text available through open access at http://escholarship.org/uc/uciem_cpcem DOI: 10.5811/cpcem.2017.3.33373 Skin necrosis is a relatively rare, potentially fatal side effect of warfarin. It is most commonly reported within 10 days of initiation of therapy in warfarin-naïve patients. We report an atypical case of warfarin-induced skin necrosis upon recommencement of warfarin in a non-naïve warfarin patient. [Clin Pract Cases Emerg Med. 2017;1(4):359–361.] INTRODUCTION were significant for a normal platelet level of 180,000/mm,³ Warfarin is currently the most widely prescribed oral partial thromboplastin time of 27.7 sec, prothrombin time of anticoagulant in North America. Thrombosis is a rare, 21.8 sec, and an international normalized ratio (INR) of 1.87. paradoxical, and potentially fatal adverse effect of the drug. Computerized tomography (CT) of the abdomen with and Skin necrosis occurs secondary to the development of without intravenous contrast showed no evidence of microthrombi and endothelial cell damage in the vessels of malignancy or hemorrhage. dermal and subcutaneous tissues. Since this rare The patient had been on the same warfarin regimen (7.5mg complication was first recognized in 1943, there have been three days a week and 10mg four days a week) for two years an estimated 300 cases reported, affecting approximately prior to presentation to our ED; it had been initiated after the 0.01-0.1% of patients on the drug.1 Typically, warfarin- development of a deep vein thrombosis and pulmonary induced skin necrosis presents within three to ten days of embolism.
    [Show full text]
  • Sepsis As a Cause of Acquired Protein C and Protein S Deficiency- a Case Report and Literature Review
    Central JSM Clinical Case Reports Case Report *Corresponding author Arun Kannan, Internal Medicine, Canton Medical Education Foundation, 1501 N Campbell Ave PO BOX Sepsis as a Cause of Acquired 245212 Tucson AZ 85712, USA, Tel: 3304121641; Fax: 5206265721; Email: Submitted: 14 December 2014 Protein C and Protein S Accepted: 30 December 2013 Published: 31 December 2013 Deficiency- a Case Report and Copyright © 2014 Kannan et al. Literature Review OPEN ACCESS Arun Kannan*, Sweta Chandra, Jose Lizcano, Christie Murphy Keywords Internal Medicine, Canton Medical Education Foundation, USA • Sepsis • Warfarin • Skin necrosis Abstract • Protein C, Protein S Warfarin Induced Skin Necrosis is a well-known and dreaded complication in patients who is being started on warfarin without adequate bridging with other anticoagulants. The mechanism is thought to be due to protein C deficiency acquired after initial exposure to warfarin. We present a rather unusual cause of protein C deficiency due to sepsis resulting in warfarin induced skin necrosis. 43 year old lady who has been on chronic warfarin therapy secondary to anti phospholipid syndrome was admitted to the hospital for acute ischemic cerebellar stroke. Warfarin was held due to acute thrombocytopenia. She was discharged to a facility after restarting the warfarin at the same dose. She presented back to the hospital with septic shock due to pneumonia. She was found to have multiple necrotic areas consistent with skin necrosis. Unfortunately, patient died due to multi organ failure despite goal directed therapy. This case demonstrates the importance of recognizing the sepsis as an acquired cause of protein C deficiency. ABBREVIATIONS therapy for 10 years was admitted to the hospital.
    [Show full text]
  • Warfarin Therapy: Tips and Tools for Better Control
    David A. Garcia, MD; Michael J. Schwartz, MD Anticoagulation Clinic, Warfarin therapy: University of New Mexico Health Sciences Center, Albuquerque (Dr. Garcia); Tips and tools for better control Health Services at Columbia University, New York, NY (Dr. Schwartz, retired) Monitoring patients on warfarin therapy is challenging. [email protected] Th e tools highlighted here—from online forums and Dr. Garcia reported that he receives Web-based dosing calculators to patient education research support from, and serves as a consultant to, Bristol-Myers materials and self-monitors—can help. Squibb and serves as a consultant to Boehringer Ingelheim; Dr. Schwartz reported that he has no potential confl ict of interest relevant to this article. pproximately 4 million Americans are receiving long- PRACTICE term oral anticoagulation therapy to reduce the risk of RECOMMENDATIONS Aprimary and secondary thromboembolism.1,2 And, as › INR testing by an anti- the population ages, the number of patients on lifelong thera- coagulation management py with warfarin—the only oral anticoagulant available in the service or private clinician United States until dabigatran was approved by the US Food can be reduced to intervals of and Drug Administration late last year3—is expected to grow.4 as long as 4 weeks, but should Such patients present a challenge for family physicians. be more frequent when dos- Warfarin is notorious for having both a narrow therapeutic ing adjustments occur. B index and numerous drug and dietary interactions.5,6 To safe- › Weekly patient self-testing guard patients on warfarin therapy, frequent, and diligent, is associated with comparable monitoring is required.
    [Show full text]
  • Understanding Calcinosis and Calciphylaxis
    PRACTICE DEVELOPMENT Understanding calcinosis and calciphylaxis KEY WORDS Calcinosis cutis is a rare cause of non-healing leg ulceration. There are many factors Calcinosis cutis that can delay the healing of venous leg ulceration and the deposition of calcium in Calciphylaxis the skin known as calcinosis cutis is one of these factors. There are five distinct forms: Warfarin-induced skin dystrophic calcification, metastatic calcification, idiopathic calcification, iatrogenic necrosis calcification and calciphylaxis. Warfarin skin necrosis has common clinical features with calciphylaxis and is therefore included in this article, which describes the types of calcinosis cutis, their clinical presentations and limited treatment options. The aim is to highlight these unusual causes and to assist healthcare professionals when faced with a non-healing ulcer. eg ulceration can be defined as a defect in neurotransmission and the blood coagulation the dermis located on the leg (Franks et al, pathway. At a cellular level, it is implicated in 2016). Leg ulceration is a significant clinical cell-to-cell communication (Walshe and Fairley, Lproblem with the majority attributing venous 1995). In the skin, it is specifically concerned with hypertension as the underlying disease process with keratinocyte proliferation, differentiation and venous leg ulceration affecting 1% of the population adhesion (Smith and Yamada, 2002). in the western world (Posnett et al, 2009). However, The level of serum calcium is closely there is a multitude of causative factors of leg ulcers, controlled by the parathyroid hormone. with the term leg ulcer purely signifying the clinical Regardless of this regulation, it is possible for manifestation and not the underlying aetiology.
    [Show full text]
  • Clinical Predictors and Genetic Determinants of Response to Warfarin Therapy in Kenyan Patients David Gitonga Nyamu
    UNIVERSITY OF NAIROBI CLINICAL PREDICTORS AND GENETIC DETERMINANTS OF RESPONSE TO WARFARIN THERAPY IN KENYAN PATIENTS DAVID GITONGA NYAMU, BPharm (UoN), MPharm (UoN), Fellow, Implementation Science (UoN/UMB) U80/52841/2018 Thesis Submitted in Fulfilment of Requirements for the Award of Doctor of Philosophy (PhD) in Clinical Pharmacy of the University of Nairobi Department of Pharmaceutics & Pharmacy Practice 2019 i ii SIMILARITY INDEX AND ORIGINALITY REPORT iii iv DEDICATION This work is dedicated to my family members, especially my wife, Lydia Gitonga, and our children, Alvin Gitonga and Belva Gitonga, who kept on motivating and reminding me that I was equal to the task whenever I felt down. Additionally, you patiently missed me at home during the tedious data collection, analysis and Thesis writing. Special dedication to my parents, for your endless love towards academics and for imparting the value of education on me early in childhood. v ACKNOWLEDGEMENTS I wish to recognize and thank all my supporters of academic dreams and aspiration throughout my entire education life. I wish to sincerely thank my great Supervisors, Professors: A.N. Guantai, G.O. Osanjo and E. Aklillu, for your relentless guidance and instilling in me the spirit of hard work through your very constructive criticisms. Thank you for taking huge portions of your busy schedules and dedicating it to my work without a single penny. Special gratitude to Professor Osanjo for thoroughly scrutinizing what went on the paper. Exceptional acknowledgements to Professor Guantai for your persistence and driving force towards completion of this Thesis. Many thanks to Institutional Review Board, Kenyatta National Hospital/University of Nairobi- Ethics and Research Committee (KNH/UoN-ERC) for approving the study protocol.
    [Show full text]
  • Warfarin-Induced Breast Necrosis: a Case Report
    CASE REPORT Warfarin-Induced Breast Necrosis: A Case Report Aghygh Heidari1, Feridoun Sabzi2 1 Department of Anesthesiology, Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran 2 Department of Cardiovascular Surgery, Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran Received: 2 Feb. 2016; Accepted: 6 Oct. 2016 Abstract- Warfarin-induced Breast necrosis (WIBN) is an exceedingly rare sequel to warfarin therapy. A close relationship was confirmed between congenital deficiency of protein C and S and warfarin usage. A predilection for this complication has been reported in fatty middle-aged women who are managing by warfarin. The sudden eruption of the bullous lesion, within mean three days after starting of warfarin therapy with or without echymous or petechia is the first sign of WIBN. The maintenance of INR in the low normal range, reducing the loading doses, especially in fatty cases may be a preventive measure in reducing risk and incidence of breast necrosis in the high-risk subjects. Early diagnosis and management are important to prevent significant tissue loss. A rare case of warfarin-related necrosis of the left breast following a mitral valve replacement is reported. Current knowledge and the preventing methods and treatment of this rare complication are reviewed. © 2018 Tehran University of Medical Sciences. All rights reserved. Acta Med Iran 2018;56(4):281-284. Keywords: Warfarin; Necrosis; Breast Introduction Early diagnosis of this rare clinical complication of warfarin allows the cardiac surgeon and cardiologist to Skin necrosis following warfarin usage has a wide make a preventive measure for progression of the range of incidence from 0.01 in low-risk subjects to disease.
    [Show full text]
  • Probable Fondaparinux-Associated Bullous Hemorrhagic Dermatosis
    PRACTICE | CASES CPD Probable fondaparinux-associated bullous hemorrhagic dermatosis Catherine Anne Lovatt MD, Wen Qing Wendy Ye MD MSc, Haroon Yousuf MD MHSc n Cite as: CMAJ 2021 May 31;193:E801-4. doi: 10.1503/cmaj.202747 90-year-old woman was admitted to a tertiary hospital with hypoxia secondary to pulmonary edema and KEY POINTS on going antibiotic therapy following an infected hip • Bullous hemorrhagic dermatosis is an uncommon nonimmune prosthesis.A The patient’s medical history included heparin- adverse drug reaction to heparin-based anticoagulants induced thrombocytopenia following administration of dalte- including unfractionated heparin, low-molecular-weight parin, atrial fibrillation (CHADS2 score of 3) and lower gastrointes- heparin and fondaparinux that typically occurs within 7 days of tinal bleeding related to diverticular disease. The patient did not drug exposure. report any skin allergies. On admission, she was 4 weeks post- • The reaction is more common in older adults, and lesions are usually found on the extremities. removal of right hip hardware, débridement and revision to a cemented right hip hemiarthroplasty for methicillin-sensitive • There are typically no changes to coagulation tests such as the international normalized ratio, partial thromboplastin time or Staphylococcus aureus infection, and was completing a 6-week the prothrombin time. course of cephalexin and rifampin. She had previously taken • Bullous hemorrhagic dermatosis is self-resolving, although apixaban for stroke prophylaxis but, before admission, her apixa- careful monitoring of bleeding, and supportive management ban was switched to warfarin because of its interaction with such as wound care and transfusion of blood products, may rifampin. However, given the interaction between warfarin and be required.
    [Show full text]
  • Allentown Cmeconference
    ALLENTOWN CME CONFERENCE Sam Study Group - Early Childhood Illness............................................................................................. Menopause and Post Gynecological Reproductive Care ....................................................................... Pulmonary Function Tests – Basic Interpretation for Primary Care ...................................................... Dyslipidemia – New Guidelines .............................................................................................................. Transitioning Patients with Autism from Pediatric to Adult Practices ................................................... Herbs, Supplements and Athletes .......................................................................................................... Tools to Treat Adult Patients with Obesity: An Update on Bariatric Surgery and Pharmacologic Agents Case Studies of Common Behavioral Health Scenarios.......................................................................... Opioid Prescribing: Safe Practice, Changing Lives ................................................................................. Act 31 Child Abuse Recognition .............................................................................................................. Integrating Genetic Testing into Family Medicine - Part I, an Overview .............................................. Drugs of Abuse .......................................................................................................................................
    [Show full text]
  • Mallory Prelims 27/1/05 1:16 Pm Page I
    Mallory Prelims 27/1/05 1:16 pm Page i Illustrated Manual of Pediatric Dermatology Mallory Prelims 27/1/05 1:16 pm Page ii Mallory Prelims 27/1/05 1:16 pm Page iii Illustrated Manual of Pediatric Dermatology Diagnosis and Management Susan Bayliss Mallory MD Professor of Internal Medicine/Division of Dermatology and Department of Pediatrics Washington University School of Medicine Director, Pediatric Dermatology St. Louis Children’s Hospital St. Louis, Missouri, USA Alanna Bree MD St. Louis University Director, Pediatric Dermatology Cardinal Glennon Children’s Hospital St. Louis, Missouri, USA Peggy Chern MD Department of Internal Medicine/Division of Dermatology and Department of Pediatrics Washington University School of Medicine St. Louis, Missouri, USA Mallory Prelims 27/1/05 1:16 pm Page iv © 2005 Taylor & Francis, an imprint of the Taylor & Francis Group First published in the United Kingdom in 2005 by Taylor & Francis, an imprint of the Taylor & Francis Group, 2 Park Square, Milton Park Abingdon, Oxon OX14 4RN, UK Tel: +44 (0) 20 7017 6000 Fax: +44 (0) 20 7017 6699 Website: www.tandf.co.uk All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention.
    [Show full text]
  • Purpura Fulminanis
    ISSN: 2689-4610 Case Report JOJ Dermatol & Cosmet Volume 1 Issue 3 - December 2018 Copyright © All rights are reserved by Khadiga Ahmed Ismail DOI: 10.19080/JOJDC.2018.01.555564 Purpura Fulminanis Mahmoud Khalifa Marzouq1, Khadiga Ahmed Ismail2,3*, Ahmed Mahmoud Khalifa4 and Osama Mahmoud Khalifa5 1Consaltant of Dermatology and Venereology, King Faisal specialized Hospital, Saudi Arabia 2Department of Laboratory Medicine, Taif University, Saudi Arabia 3Department of Parasitology, Ain-Shams University, Egypt 4Department Forensic and Toxicology, Ain-Shams University, Egypt 5Faculty of Medicine, Ain-Shams University, Egypt Submission: December 05, 2018; Published: December 20, 2018 *Corresponding author: Khadiga Ahmed Ismail, Department of Laboratory Medicine & Department of Parasitology, King Faisal specialized Hospital & Ain-Shams University, Saudi Arabia Abstract Purpura Fulminanis (PF) is an emergency progressive thrombotic disorder in which there is skin necrosis, Disseminated Dntravascular Coagulation (DIC) and multiorgan failure. It may complicate severe sepsis or may occur as an autoimmune response to other infection as varicella. management promptly. We present a case of purpura fulminanis who died, unfortunately, after 8 days due to severe sepsis. Also, it may associate with severe heritable deficiency of protein C or protein S. PF is a rapidly fatal disease, so it needs rapid diagnosis and Keywords: Purpura Fulminanis; Disseminated Dntravascular Coagulation; Coronary Artery Bypass Grafting; Disseminated Intravascular Coagulation;
    [Show full text]
  • Warfarin-Induced Skin Necrosis Within Psoriatic Plaques
    UC Davis Dermatology Online Journal Title Warfarin-induced skin necrosis within psoriatic plaques Permalink https://escholarship.org/uc/item/4gf5r5qk Journal Dermatology Online Journal, 25(6) Author Eichhoff, Gerhard Publication Date 2019 DOI 10.5070/D3256044495 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 25 Number 6| June 2019| Dermatology Online Journal || Photo Vignette 25(6):13 Warfarin-induced skin necrosis within psoriatic plaques Gerhard Eichhoff MD PhD FRACP Affiliations: Dermatology Service Capital & Coast and Hutt Valley District Health Board, Wellington Regional Hospital, New Zealand Corresponding Author: Gerhard Eichhoff MD, PhD, Wellington Regional Hospital, PB 7902, New Zealand, Tel: 64-43855999, Email: [email protected] dermatosis on the same place as that of healed Abstract cutaneous lesions [7]. In current medical practice, A myriad of different phenomena exist in the warfarin, a vitamin K antagonist, is one of the most dermatological literature which are based on the frequently used anticoagulants for primary and concept of locus minores resistentiae. The most secondary prevention of thromboembolic disorders. commonly described phenomenon is the Koebner With a prevalence of 0.01%–0.1%, warfarin-induced phenomenon, which is classically associated with the skin necrosis (WISN) is a rare complication with a high emergence of psoriatic lesions post trauma. Warfarin- morbidity [3]. The presented case describes WSIN induced skin necrosis (WISN) is a rare but severe side effect that leads to necrosis of the skin, within psoriatic plaques. predominantly on areas with increased subcutaneous fat.
    [Show full text]
  • Hypercoagulability Syndromes
    REVIEW ARTICLE Hypercoagulability Syndromes Robert H. Thomas, MD ypercoagulability can be defined as the tendency to have thrombosis as a result of certain inherited and/or acquired molecular defects. Clinical manifestations of hy- percoagulability can be devastating and even lethal. In the past 20 years, the origin of most of these diverse hypercoagulability syndromes has been elucidated. Cur- Hrently, hypercoagulability disorders can be correctly diagnosed in approximately 80% to 90% of patients. Defining the cause of hypercoagulability may determine the type and duration of treat- ment for the associated thrombosis. The discovery of an occult carcinoma allows for the possibil- ity of early and possibly curative treatment. Finding a genetic defect in coagulation allows for test- ing of asymptomatic family members as well. The purpose of this review is to provide internists with a logical approach to the identification and treatment of hypercoagulability syndromes. Arch Intern Med. 2001;161:2433-2439 Most commonly, thrombosis is the result depending on the ethnic backgrounds of of more than one “hit.” For example, pa- persons in a particular geographic area. tients with the factor V Leiden defect may be asymptomatic until they start taking oral Disorder Incidence, % contraceptives. Patients with antithrom- Antiphospholipid antibody 28 syndrome bin deficiency may go on without inci- Activated protein C resistance 25 dent until they undergo a hernia repair. Elevated coagulation factor VIII 25 Also, multiple genetic defects predispose levels one to thrombosis much more than does Malignancy 15 a single defect.1,2 Some defects are known Sticky platelet syndrome 14 to be more powerful predictors than oth- Protein C deficiency 10 ers.
    [Show full text]